Radiotherapy is Not Associated With Reduced Quality of Life and Cognitive Function in Patients Treated for Nonfunctioning Pituitary Adenoma

Beek, André P van; Bergh, Alphons C.M. van den; Berg, Linda; Berg, Gerrit van den; Keers, Joost C.; Langendijk, Johannes A.; Wolffenbuttel, Bruce H. R.

doi:10.1016/j.ijrobp.2007.01.017

Cited by 56 publications

(55 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgery was performed in both centers by specialized pituitary neurosurgeons between 1975 and 2008. RT was given postoperatively as previously described (21). SSTA were prescribed postoperatively in case of persistent or recurrent disease in accordance with the standard of care at the time of treatment (1).…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma

Netea‐Maier²,

Berg³

et al. 2012

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objective: To assess the influence of long-acting somatostatin analogs (SSTA) after initial pituitary surgery on long-term health-related quality of life (HR-QoL) in relation to disease control in patients with acromegaly. Design: This is a cross-sectional study in two tertiary referral centers in The Netherlands. Patients and methods: One hundred and eight patients with acromegaly, in whom transsphenoidal (nZ101, 94%) or transcranial (nZ7, 6%) surgery was performed. Subsequently, 46 (43%) received additional radiotherapy and 41 (38%) were on postoperative treatment with SSTA because of persistent or recurrent disease at the time of study. All subjects filled in standardized questionnaires measuring HR-QoL. Disease control at the time of study was assessed by local IGF1 SDS. Results: IGF1 SDS were slightly higher in patients treated with SSTA in comparison with patients without use of SSTA (0.85G1.52 vs 0.25G1.21, PZ0.026), but the percentage of patients with insufficient control (IGF1 SDS O2) was not different (17 vs 9%, PZ0.208). Patients using SSTA reported poorer scores on most subscales of the RAND-36 and the acromegaly QoL and on all subscales of the multidimensional fatigue inventory-20. A subgroup analysis in patients with similar IGF1 levels (SSTAC, nZ26, IGF1 SDS 0.44G0.72 vs SSTAK, nZ44, IGF1 SDS 0.41G0.65) revealed worse scores on physical functioning, physical fatigue, reduced activity, vitality, and general health perception across all HR-QoL questionnaires in patients treated with SSTA. Conclusion: QoL is impaired in association with the need for prolonged postoperative therapy by SSTA in patients with acromegaly despite similar IGF1 levels.

show abstract

Section: Study Populationmentioning

confidence: 99%

“…In Groningen, plasma IGF1 was measured by RIA after acid-ethanol extraction (Nichols Institute of Diagnostics, San-Juan Capistrano, CA, USA) (21). In Nijmegen, serum IGF1 was measured by an in-house RIA (23).…”

Section: Laboratory Assaysmentioning

confidence: 99%

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma

Netea‐Maier²,

Berg³

et al. 2012

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Evidence has been presented that suggests radiotherapy for pituitary tumors does not reduce the quality of life or cognitive function in these patients. 24,53 Several LINAC-based trials report similar results. 35 Recent experience with GKS has been reported in the treatment of Cushing disease, acromegaly, and Nelson syndrome.…”

Section: Pituitary Tumorsmentioning

confidence: 78%

“…Complications of radiosurgery are relatively low. 43,53 Compiled data from Ͼ 1300 patients by Shrieve and colleagues 46 demonstrated that 0.3% developed subsequent blindness, 0.7% developed visual field defects, and 0.9% developed oculomotor deficits after radiosurgery for pituitary tumors. Evidence has been presented that suggests radiotherapy for pituitary tumors does not reduce the quality of life or cognitive function in these patients.…”

Section: Pituitary Tumorsmentioning

confidence: 99%

Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors

Johnson

Loredo

Slater

2008

FOC

View full text Add to dashboard Cite

✓ Historically, radiation therapy has been used extensively in the treatment of malignant and aggressive intracranial tumors, and the importance of its role has been repeatedly verified by prolonged patient survival rates and increased tumor control. As more modern capabilities are employed in surgery and radiotherapy, attention is being directed to the utility of radiation as either primary or secondary treatment of benign tumors. Specifically, primary treatment encompasses irradiation of small benign tumors without biopsy confirmation of tumor type; secondary treatment involves postoperative radiation therapy, with the possibility that less-aggressive tumor resection may be performed in areas that have a higher probability of resultant neurological deficit. Current literature suggests that this is not only a possible treatment strategy, but that it may be superior to more radical resection in some cases, for example, in vestibular schwannomas and meningiomas. This article provides an overview of factors to consider in the use of radiation therapy and reviews the relationships between radiation and surgery, notably the unique complementary role each plays in the treatment of benign intracranial tumors.

show abstract

“…Some studies demonstrated that having received radiotherapy can impair mental health 67 or energy levels of NFA patients, 66 without affecting their general health perception. 43,65,84 In conclusion, specific characteristics of NFA patients, such as female gender, hypopituitarism (especially hypogonadism and GH deficiency) or tumour recurrence seem to be related with impaired QoL. Radiological and clinical monitoring, hormone replacement and better sleep quality will ameliorate the perception of health status.…”

Section: Non-functioning Pituitary Adenomasmentioning

confidence: 94%

Improving Quality of Life in Patients with Pituitary Tumours

Crespo¹,

Santos²,

Resmini³

et al. 2014

US Endocrinology

View full text Add to dashboard Cite

Evaluation of health-related quality of life (QoL) in people with pituitary tumours has received much attention over the last 10-15 years. Most of them show impaired QoL, but little is known about how to prevent impairment or how to improve QoL. Our aim is to review what is known about QoL in pituitary tumours patients and to highlight the areas worth improving, for the patient's well being. The article has four sections: acromegaly, Cushing's syndrome, prolactinomas and non-functioning adenomas. Control of comorbidities is usually an important factor to prevent QoL impairment; however, each disease has specific characteristics that should be properly addressed in order to obtain full patient recovery after successful therapy.

show abstract

Radiotherapy is Not Associated With Reduced Quality of Life and Cognitive Function in Patients Treated for Nonfunctioning Pituitary Adenoma

Cited by 56 publications

References 28 publications

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors

Improving Quality of Life in Patients with Pituitary Tumours

Contact Info

Product

Resources

About